Medicamen Organics Ltd Financials
Company Logo

Medicamen Organics Ltd Financial Statement

Medicamen Organics Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Medicamen Organics Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual37.09
Operating Expenses Annual31.55
Operating Profit Annual5.64
Interest Annual0.51
Depreciation0.74
Net Profit Annual3.27
Tax Annual1.12

Medicamen Organics Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.55
Cash Flow from Operations-4.91
Cash Flow from Investing-2.62
Cash Flow from Financing10.25
Cash Flow at the End3.27

Medicamen Organics Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)15.26
PBIT Margin (%)13.27
PBT Margin (%)-11.35
Net PROFIT Margin (%)8.82
Return On Networth / Equity (%)14.54
Return On Networth /Employed (%)14.04
Return On Assets (%)9.35
Total Debt / Equity (X)0.55
Asset Turnover Ratio (%)1.06

Medicamen Organics Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual10.13
Total Current Assets Annual43.42
Non Current Assets Annual14.03
Total Shareholders Funds Annual29.72
Total Assets Annual57.44

Medicamen Organics Ltd Earning Calls

No Data Availabe

FAQS on Medicamen Organics Ltd Financials

As of Sep 11, 2025, Medicamen Organics Ltd has a market capitalization of 25.39 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Medicamen Organics Ltd is with a debt-to-equity ratio of 0.41.

In FY 2024 , Medicamen Organics Ltd recorded a total revenue of approximately 37.09 Cr marking a significant milestone in the company's financial performance.

Medicamen Organics Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.3% annually, respectively..

Medicamen Organics Ltd's current PE ratio is 7.76.

Medicamen Organics Ltd's ROCE averaged 13.1% from the FY ending March 2023 to 2025, with a median of 11.7%. It peaked at 18.2% in March 2024, reflecting strong capital efficiency over the period..

Medicamen Organics Ltd's latest EBIT is Rs. 4.90 Cr, surpassing the average EBIT of Rs. 3.99 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions